학술논문
Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C
Document Type
article
Author
Tang, Juanjie; Novak, Tanya; Hecker, Julian; Grubbs, Gabrielle; Zahra, Fatema Tuz; Bellusci, Lorenza; Pourhashemi, Sara; Chou, Janet; Moffitt, Kristin; Halasa, Natasha B; Schwartz, Stephanie P; Walker, Tracie C; Tarquinio, Keiko M; Zinter, Matt S; Staat, Mary A; Gertz, Shira J; Cvijanovich, Natalie Z; Schuster, Jennifer E; Loftis, Laura L; Coates, Bria M; Mack, Elizabeth H; Irby, Katherine; Fitzgerald, Julie C; Rowan, Courtney M; Kong, Michele; Flori, Heidi R; Maddux, Aline B; Shein, Steven L; Crandall, Hillary; Hume, Janet R; Hobbs, Charlotte V; Tremoulet, Adriana H; Shimizu, Chisato; Burns, Jane C; Chen, Sabrina R; Moon, Hye Kyung; Lange, Christoph; Randolph, Adrienne G; Khurana, Surender
Source
Nature Communications. 13(1)
Subject
Language
Abstract
Neutralization capacity of antibodies against Omicron after a prior SARS-CoV-2 infection in children and adolescents is not well studied. Therefore, we evaluated virus-neutralizing capacity against SARS-CoV-2 Alpha, Beta, Gamma, Delta and Omicron variants by age-stratified analyses (5 years of age. As expected, convalescent pediatric COVID-19 and MIS-C cohorts demonstrate higher neutralization titers than hospitalized acute COVID-19 patients. Overall, children and adolescents show some loss of cross-neutralization against all variants, with the most pronounced loss against Omicron. In contrast to SARS-CoV-2 infection, children vaccinated twice demonstrated higher titers against Alpha, Beta, Gamma, Delta and Omicron. These findings can influence transmission, re-infection and the clinical disease outcome from emerging SARS-CoV-2 variants and supports the need for vaccination in children.